Inhibitors of Farnesyltransferase: A Rational Approach to Cancer Chemotherapy?

Journal of Medicinal Chemistry

Volumn 47, Issue 8, 2004, Pages 1869-1878

  Bell, Ian M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR;

CANCER; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CRYSTALLOGRAPHY; ENZYME INHIBITION; ENZYME STRUCTURE; FARNESYLATION; MONOTHERAPY; PRENYLATION; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG DESIGN; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; NEOPLASMS;

EID: 1842450537     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0305467     Document Type: Review

References (76)

1. Shields, J. M.; Pruitt, K.; McFall, A.; Shaub, A.; Der, C. J. Understanding Ras: "It Ain't Over 'Til It's Over." Trends Cell Biol. 2000, 10, 147-154.
2. Bos, J. L. Ras Oncogenes in Human Cancer: A Review. Cancer Res. 1989, 49, 4682-4689.
3. Clark, G. J.; Der, C. J. Ras Proto-oncogene Activation in Human Malignancy. In Cellular Cancer Markers; Garrett, C. T., Sell, S., Eds.; Humana Press: Totowa, NJ, 1995; pp 17-52.
4. Willumsen, B. M.; Norris, K.; Papageorge, A. G.; Hubbert, N. L.; Lowy, D. R. Harvey Murine Sarcoma Virus p21 Ras Protein: Biological and Biochemical Significance of the Cysteine Nearest the Carboxy Terminus. EMBO J. 1984, 3, 2581-2585.
5. Casey, P. J.; Solski, P. A.; Der, C.; Buss, J. E. p21 Ras Is Modified by a Farnesyl Isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8323-8327.
6. Leonard, D. M. Ras Farnesyltransferase: A New Therapeutic Target. J. Med. Chem. 1997, 40, 2971-2990.
7. Zhang, F. L.; Casey, P. J. Protein Prenylation: Molecular Mechanisms and Functional Consequences. Annu. Rev. Biochem. 1996, 65, 241-269.
8. Fu, H.-W.; Casey, P. J. Enzymology and Biology of CaaX Protein Prenylation. Recent Prog. Horm. Res. 1999, 54, 315-343.
9. Long, S. B.; Casey, P. J.; Beese, L. S. Reaction Path of Protein Farnesyltransferase at Atomic Resolution. Nature (London) 2002, 419, 645-650.
10. Hightower, K. E.; Huang, C.; Casey, P. J.; Fierke, C. A. H-Ras Peptide and Protein Farnesyltransferase as an Ionized Thiolate. Biochemistry 1998, 37, 15555-15562.
11. as of Peptide Substrates Bound as Zinc Thiolates. Biochemistry 1999, 38, 13138-13146.
12. Tschantz, W. R.; Furfine, E. S.; Casey, P. J. Substrate Binding Is Required for Release of Product from Mammalian Protein Farnesyltransferase. J. Biol. Chem. 1997, 272, 9989-9993.
13. Long, S. B.; Hancock, P. J.; Kral, A. M.; Hellinga, H. W.; Beese, L. S. The Crystal Structure of Human Protein Farnesyltransferase Reveals the Basis for Inhibition by CaaX Tetrapeptides and Their Mimetics. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12948-12953.
14. Bell, I. M.; Gallicchio, S. N.; Abrams, M.; Beese, L. S.; Beshore, D. C. ; Bhimnathwala, H.; Bogusky, M. J.; Buser, C. A.; Culberson, J. C.; Davide, J.; Ellis-Hutchings, M.; Fernandes, C.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D. ; Heimbrook, D. C.; Homnick, C. F.; Huber, H. E.; Huff, J. R.; Kassahun, K.; Koblan, K. S.; Kohl, N. E.; Lobell, R. B.; Lynch, J. J.; Robinson, R.; Rodrigues, A. D.; Taylor, J. S.; Walsh, E. S.; Williams, T. M.; Zartman, C. B. 3-Aminopyrrolidinone Farnesyltransferase Inhibitors: Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency. J. Med. Chem. 2002, 45, 2388-2409.
15. Strickland, C. L.; Weber, P. C.; Windsor, W. T.; Wu, Z.; Le, H. V.; Albanese, M. M.; Alvarez, C. S.; Cesarz, D.; del Rosario, J.; Deskus, J.; Mallams, A. K.; Njoroge, F. G.; Piwinski, J. J.; Remiszewski, S.; Rossman, R. R.; Taveras, A. G.; Vibulbhan, B.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K. Tricyclic Farnesyl Protein Transferase Inhibitors: Crystallographic and Calorimetric Studies of Structure-Activity Relationships. J. Med. Chem. 1999, 42, 2125-2135.
16. Sebti, S. M.; Hamilton, A. D. New Approaches to Anticancer Drug Design Based on the Inhibition of Farnesyltransferase. Drug Discovery Today 1998, 3, 26-33.
17. Williams, T. M. Inhibitors of Protein Prenylation 1999. Expert Opin. Ther. Pat. 1999, 9, 1263-1280.
18. Rowinsky, E. K.; Patnaik, A. The Development of Protein Farnesyltransferase and Other Ras-Directed Therapeutics for Malignant Diseases. Emerging Drugs 2000, 5, 161-199.
19. Dinsmore, C. J.; Bell, I. M. Inhibitors of Farnesyltransferase and Geranylgeranyltransferase-I for Antitumor Therapy: Structure-Based Design, Conformational Constraint and Biological Activity. Curr. Top. Med. Chem. 2003, 3, 1075-1093.
20. Taveras, A. G.; Kirschmeier, P.; Baum, C. M. Sch-66336 (Sarasar) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations. Curr. Top. Med. Chem. 2003, 3, 1103-1114.
21. Kohl, N. E.; Omer, C. A.; Conner, M. W.; Anthony, N. J.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Gomez, R. P.; Graham, S. L.; Hamilton, K.; Handt, L. K.; Hartman, G. D.; Koblan, K. S.; Kral, A. M.; Miller, P. J.; Mosser, S. D.; O'Neill, T. J.; Rands, E.; Schaber, M. D.; Gibbs, J. B.; Oliff, A. Inhibition of Farnesyltransferase Induces Regression of Mammary and Salivary Carcinomas in Ras Transgenic Mice. Nat. Med. 1995, 1, 792-797.
22. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes. J. Biol. Chem. 1995, 270, 26802-26806.
23. Stephens, T. C.; Wardleworth, M. J.; Matusiak, Z. S.; Ashton, S. E.; Hancox, U. J.; Bate, M.; Ferguson, R.; Boyle, T. AZD3409, a Novel, Oral, Protein Prenylation Inhibitor with Promising Preclinical Antitumor Activity. Proc. Am. Assoc. Cancer Res. 2003, 44, R4870.
24. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Bock, R. L.; Conner, M. W.; Davide, J. P.; Hamilton, K.; Koblan, K. S.; Kohl, N. E.; Kral, A. M.; Mosser, S. D.; Omer, C. A.; Pompliano, D. L.; Rands, E.; Schaber, M. D.; Shah, D.; Wilson, F. R.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Smith, R. L. 2-Substituted Piperazines as Constrained Amino Acids. Application to the Synthesis of Potent, Non Carboxylic Acid Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 1345-1348.
25. Anthony, N. J.; Gomez, R. P.; Schaber, M. D.; Mosser, S. D.; Hamilton, K. A.; O'Neill, T. J.; Koblan, K. S.; Graham, S. L.; Hartman, G. D.; Shah, D.; Rands, E.; Kohl, N. E.; Gibbs, J. B.; Oliff, A. I. Design and in Vivo Analysis of Potent Nonthiol Inhibitors of Farnesyl Protein Transferase. J. Med. Chem. 1999, 42, 3356-3368.
26. Williams, T. M.; Bergman, J. M.; Brashear, K.; Breslin, M. J.; Dinsmore, C. J.; Hutchinson, J. H.; MacTough, S. C.; Stump, C. A.; Wei, D. D.; Zartman, C. B.; Bogusky, M. J.; Culberson, J. C.; Buser-Doepner, C.; Davide, J.; Greenberg, I. B.; Hamilton, K. A.; Koblan, K. S.; Kohl, N. E.; Liu, D.; Lobell, R. B.; Mosser, S. D.; O'Neill, T. J.; Rands, E.; Schaber, M. D.; Wilson, F.; Senderak, E.; Motzel, S. L.; Gibbs, J. B.; Graham, S. L.; Heimbrook, D. C.; Hartman, G. D.; Oliff, A. I.; Huff, J. R. N-Arylpiperazinone Inhibitors of Farnesyltransferase: Discovery and Biological Activity. J. Med. Chem. 1999, 42, 3779-3784.
27. Merck & Co., Inc. Unpublished results.
28. Huber, H. E.; Robinson, R. G.; Watkins, A.; Nahas, D. D.; Abrams, M. T.; Buser, C. A.; Lobell, R. B.; Patrick, D.; Anthony, N. J.; Dinsmore, C. J.; Graham, S. L.; Hartman, G. D.; Lumma, W. C.; Williams, T. M.; Heimbrook, D. C. Anions Modulate the Potency of Geranylgeranyl-Protein-Transferase-I Inhibitors. J. Biol. Chem. 2001, 276, 24457-24465.
29. Lobell, R. B.; Liu, D.; Buser, C. A.; Davide, J. P.; DePuy, E.; Hamilton, K.; Koblan, K. S.; Lee, Y.; Mosser, S.; Motzel, S. L.; Abbruzzese, J. L.; Fuchs, C. S.; Rowinsky, E. K.; Rubin, E. H.; Sharma, S.; Deutsch, P. J.; Mazina, K. E.; Morrison, B. W.; Wildonger, L.; Yao, S.-L.; Kohl, N. E. Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I. Mol. Cancer Ther. 2002, 1, 747-758.
30. Dinsmore, C. J.; Bogusky, M. J.; Culberson, J. C.; Bergman, J. M.; Homnick, C. F.; Zartman, C. B.; Mosser, S. D.; Schaber, M. D.; Robinson, R. G.; Koblan, K. S.; Huber, H. E.; Graham, S. L.; Hartman, G. D.; Huff, J. R.; Williams, T. M. Conformational Restriction of Flexible Ligands Guided by the Transferred NOE Experiment: Potent Macrocyclic Inhibitors of Farnesyltransferase. J. Am. Chem. Soc. 2001, 123, 2107-2108.
31. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
32. Ding, C. Z.; Batorsky, R.; Bhide, R.; Chao, H. J.; Cho, Y.; Chong, S.; Gullo-Brown, J.; Guo, P.; Kim, S. H.; Lee, F.; Leftheris, K.; Miller, A.; Mitt, T.; Patel, M.; Penhallow, B. A.; Ricca, C.; Rose, W. C.; Schmidt, R.; Slusarchyk, W. A.; Vite, G.; Yan, N.; Manne, V.; Hunt, J. T. Discovery and Structure-Activity Relationships of Imidazole-Containing Tetrahydrobenzodiazepine Inhibitors of Farnesyltransferase. J. Med. Chem. 1999, 42, 5241-5253.
33. Hunt, J. T.; Ding, C. Z.; Batorsky, R.; Bednarz, M.; Bhide, R.; Cho, Y.; Chong, S.; Chao, S.; Gullo-Brown, J.; Guo, P.; Kim, S. H.; Lee, F. Y. F.; Leftheris, K.; Miller, A.; Mitt, T.; Patel, M.; Penhallow, B. A.; Ricca, C.; Rose, W. C.; Schmidt, R.; Slusarchyk, W. A.; Vite, G.; Manne, V. Discovery of (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl) -4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity. J. Med. Chem. 2000, 43, 3587-3595.
34. Rose, W. C.; Lee, F. Y. F.; Fairchild, C. R.; Lynch, M.; Monticello, T.; Kramer, R. A.; Manne, V. Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor. Cancer Res. 2001, 61, 7507-7517.
35. Njoroge, F. G.; Taveras, A. G.; Kelly, J.; Remiszewski, S.; Mallams, A. K.; Wolin, R.; Afonso, A.; Cooper, A. B.; Rane, D. F.; Liu, Y.-T.; Wong, J.; Vibulbhan, B.; Pinto, P.; Deskus, J.; Alvarez, C. S.; del Rosario, J.; Connolly, M.; Wang, J.; Desai, J.; Rossman, R. R.; Bishop, W. R.; Patton, R.; Wang, L.; Kirschmeier , P.; Bryant, M. S.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; McPhail, A. T.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-[5,6]cyclohepta[1,2-b) -pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent. J. Med. Chem. 1999, 42, 2125-2135.
36. Liu, M.; Bryant, M. S.; Chen, J.; Lee, S.; Yaremko, B.; Lipari, P.; Malkowski, M.; Ferrari, E.; Nielsen, L.; Prioli, N.; Dell, J.; Sinha, D.; Syed, J.; Korfmacher, W. A.; Nomeir, A. A.; Lin, C.-C.; Wang, L.; Taveras, A. G.; Doll, R. J.; Njoroge, F. G.; Mallams, A. K.; Remiszewski, S.; Catino, J. J.; Girijavallabhan, V. M.; Kirschmeier, P.; Bishop, W. R. Antitumor Activity of SCH 66336, an Orally Bioavailable Tricyclic Inhibitor of Farnesyl Protein Transferase, in Human Tumor Xenograft Models and Wap-ras Transgenic Mice. Cancer Res. 1998, 58, 4947-4956.
37. Venet, M.; End, D.; Angibaud, P. Farnesyl Protein Transferase Inhibitor ZARNESTRA R115777-History of a Discovery. Curr. Top. Med. Chem. 2003, 3, 1095-1102.
38. End, D. W.; Smets, G.; Todd, A. V.; Applegate, T. L.; Fuery, C. J.; Angibaud, P.; Venet, M.; Sanz, G.; Poignet, H.; Skrzat, S.; Devine, A.; Wouters, W.; Bowden, C. Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro. Cancer Res. 2001, 61, 131-137.
39. Smith, V.; Rowlands, M. G.; Barrie, E.; Workman, P.; Kelland, L. R. Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line. Clin. Cancer Res. 2002, 8, 2002-2009.
40. Gelb, M. H.; Van Voorhis, W. C.; Buckner, F. S.; Yokoyama, K.; Eastman, R.; Carpenter, E. P.; Panethymitaki, C.; Brown, K. A.; Smith, D. F. Protein Farnesyl and N-Myristoyl Transferases: Piggy-Back Medicinal Chemistry Targets for the Development of Antitrypanosomatid and Antimalarial Therapeutics. Mol. Biochem. Parasitol. 2003, 126, 155-163.
41. Prendergast, G. C.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase Inhibition Causes Morphological Reversion of Ras-Transformed Cells by a Complex Mechanism That Involves Regulation of the Actin Cytoskeleton. Mol. Cell. Biol. 1994, 14, 4193-4202.
42. Sepp-Lorenzino, L.; Ma, Z.; Rands, E.; Kohl, N.; Gibbs, J. B.; Oliff, A. ; Rosen, N. A Peptidomimetic Inhibitor of Farnesyl: Protein Transferase Blocks the Anchorage-Dependent and Independent Growth of Human Tumor Cell Lines. Cancer Res. 1995, 55, 5302-5309.
43. Whyte, D. B.; Kirschmeier, P.; Hockenberry, T. N.; Nunez-Oliva, I.; James, L.; Catino, J. J.; Bishop, W. R.; Pai, J. K. K- and N-Ras are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors. J. Biol. Chem. 1997, 272, 14459-14464.
44. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Both Farnesyltransferase and Geranylgeranyltransferase I Inhibitors Are Required for Inhibition of Oncogenic K-Ras Prenylation but Each Alone Is Sufficient To Suppress Human Tumor Growth in Nude Mouse Xenografts. Oncogene 1998, 16, 1467-1473.
45. deSolms, S. J.; Ciccarone, T. M.; MacTough, S. C.; Shaw, A. W.; Buser, C. A.; Ellis-Hutchings, M.; Fernandes, C.; Hamilton, K. A.; Huber, H. E.; Kohl, N. E.; Lobell, R. B.; Robinson, R. G.; Tsou, N. N.; Walsh, E. S.; Graham, S. L.; Beese, L. S.; Taylor, J. S. Dual Protein Farnesyltransferase-Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic Agents. J. Med. Chem. 2003, 46, 2973-2984.
46. Lobell, R. B.; Omer, C. A.; Abrams, M. T.; Bhimnathwala, H. G.; Brucker, M. J.; Buser, C. A.; Davide, J. P.; deSolms, S. J.; Dinsmore, C. J.; Ellis-Hutchings, M. S.; Kral, A. M.; Liu, D.; Lumma, W. C.; Machotka, S. V.; Rands, E.; Williams, T. M.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Heimbrook, D. C.; Kohl, N. R. Evalualion of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Inhibitor Combinations in Preclinical Models. Cancer Res. 2001, 61, 8758-8768.
47. Cox, A. D.; Der, C. J. Farnesyltransferase Inhibitors: Promises and Realities. Curr. Opin. Pharmacol. 2002, 2, 388-393.
48. Feldkamp, M. M.; Lau, N.; Roncari, L.; Guha, A. Isotype-specific Ras.GTP-Levels Predict the Efficacy of Farnesyl Transferase Inhibitors against Human Astrocytomas Regardless of Ras Mutational Status. Cancer Res. 2001, 61, 4425-4431.
49. Prendergast, G. C.; Rane, N. Farnesyltransferase Inhibitors: Mechanism and Applications. Expert Opin. Invest. Drugs 2001, 10, 2105-2116.
50. Liu, A.-X.; Du, W.; Liu, J.-P.; Jessell, T. M.; Prendergast, G. C. RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors. Mol. Cell. Biol. 2000, 20, 6105-6113.
51. Chen, Z.; Sun, J.; Pradines, A.; Favre, G.; Adnane, J.; Sebti, S. M. Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice. J. Biol. Chem. 2000, 275, 17974-17978.
52. Ashar, H. R.; James, L.; Gray, K.; Carr, D.; Black, S.; Armstrong, L.; Bishop, W. R.; Kirschmeier, P. Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules. J. Biol. Chem. 2000, 275, 30451-30457.
53. Pidoux, A. L.; Allshire, R. C. Centromeres: Getting a Grip of Chromosomes. Curr. Opin. Cell. Biol. 2000, 12, 308-319.
54. Hussein, D.; Taylor, S. S. Farnesylation of Cenp-F Is Required for G2/M Progression and Degradation after Mitosis. J. Cell Sci. 2002, 115, 3403-3414.
55. Crespo, N. C.; Ohkanda, J.; Yen, T. J.; Hamilton, A. D.; Sebti, S. M. The Farnesyltransferase Inhibitor, FTI-2153, Blocks Bipolar Spindle Formation and Chromosome Alignment and Causes Prometaphase Accumulation during Mitosis of Human Lung Cancer Cells. J. Biol. Chem. 2001, 276, 16161-16167.
56. 1 Pause in Sensitive Human Tumor Cell Lines. Exp. Cell Res. 2001, 262, 17-27.
57. Moasser, M. M.; Rosen, N. The Use of Molecular Markers in Farnesyltransferase Inhibitor (FTI) Therapy of Breast Cancer. Breast Cancer Res. Treat. 2002, 73, 135-144.
58. Jiang, K.; Coppola, D.; Crespo, N. C.; Nicosia, S. V.; Hamilton, A. D.; Sebti, S. M.; Cheng, J. Q. The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis. Mol. Cell. Biol. 2000, 20, 139-148.
59. Crul, M.; de Klerk, G. J.; Swart, M.; van't Veer, L. J.; de Jong, D.; Boerrigter, L.; Palmer, P. A.; Bol, C. J.; Tan, H.; de Gast, G. C.; Beijnen, J. H.; Schellens, J. H. M. Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer. J. Clin. Oncol. 2002, 20, 2726-2735.
60. Kantarjian, H. M.; Cortes, J. E.; Rowe, J. M.; Kurzrock, R. Future Clinical Implications for Farnesyltransferase Inhibitors in Hematologic Malignancies. Semin. Hematol. 2002, 39, 36-38.
61. Adjei, A. A.; Davis, J. N.; Erlichman, C.; Svingen, P. A.; Kaufmann, S. H. Comparison of Potential Markers of Farnesyltransferase Inhibition. Clin. Cancer Res. 2000, 6, 2318-2325.
62. Karp, J. E.; Lancet, J. E.; Kaufmann, S. H.; End, D. W.; Wright, J. J.; Bol, K.; Horak, I.; Tidwell, M. L.; Liesveld, J.; Kottke, T. J.; Ange, D.; Buddharaju, L.; Gojo, I.; Highsmith, W. E.; Belly, R. T.; Hohl, R. J.; Rybak, M. E.; Thibault, A.; Rosenblatt, J. Clinical and Biologic Activity of the Farnesyltransferase Inhibitor R115777 in Adults with Refractory and Relapsed Acute Leukemias: A Phase 1 Clinical-Laboratory Correlative Trial. Blood 2001, 97, 3361-3369.
63. Johnston, S. R. D.; Hickish, T.; Houston, S.; Ellis, P. A.; Howes, A. J. ; Thibault, A. Efficacy and Tolerability of Two Dosing Regimens of R115777 (Zarnestra), a Farnesyl Protein Transferase Inhibitor, in Patients with Advanced Breast Cancer. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, 2002; Abstract 138.
64. Cunningham, D.; de Gramont, A.; Scheithauer, W.; Smakal, M.; Humblet, Y. ; Kurteva, G.; Iveson, T.; Andre, T.; Dostalova, J.; Illes, A.; Jia, X.; Palmer, P. Randomized Double-Blind Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 (Zarnestra) in Advanced Refractory Colorectal Cancer. Presented at the 8th Annual Meeting of the American Society of Clinical Oncology, 2002; Abstract 502.
65. Cortes, J.; Albitar, M.; Thomas, D.; Giles, F.; Kurzrock, R.; Thibault, A.; Rackoff, W.; Koller, C.; O'Brien, S.; Garcia-Manero, G.; Talpaz, M.; Kantarjian, H. Efficacy of the Farnesyl Transferase Inhibitor R115777 in Chronic Myeloid Leukemia and Other Hematologic Malignancies. Blood 2003, 101, 1692-1697.
66. Adjei, A. A.; Erlichman, C.; Davis, J. N.; Cutler, D. L.; Sloan, J. A.; Marks, R. S.; Hanson, L. J.; Svingen, P. A.; Atherton, P.; Bishop, W. R.; Kirschmeier, P.; Kaufmann, S. H. A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity. Cancer Res. 2000, 60, 1871-1877.
67. Lersch, C.; Van Cutsem, E.; Amado, R.; Ehninger, G.; Heike, M.; Kerr, D. ; Rothenberg, M. L.; Baum, C. M.; Zaknoen, S. L. Randomized Phase II Study of SCH 66336 and Gemcitabine in the Treatment of Metastatic Adenocarcinoma of the Pancreas. Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, 2001; Abstract 608.
68. Britten, C. D.; Rowinsky, E. K.; Soignet, S.; Patnaik, A.; Yao, S.-L.; Deutsch, P.; Lee, Y.; Lobell, R. B.; Mazina, K. E.; McCreery, H.; Pezzuli, S.; Spriggs, D. A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies. Clin. Cancer Res. 2001, 7, 3894-3903.
69. Haluska, P.; Dy, G. K.; Adjei, A. A. Farnesyl Transferase Inhibitors as Anticancer Agents. Eur. J. Cancer 2002, 38, 1685-1700.
70. Moasser, M. M.; Sepp-Lorenzino, L.; Kohl, N. E.; Oliff, A.; Balog, A.; Su, D. S.; Danishefsky, S. J.; Rosen, N. Farnesyl Transferase Inhibitors Cause Enhanced Mitotic Sensitivity'to Taxol and Epothilones. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 1369-1374.
71. Sun, J.; Blaskovich, M. A.; Knowles, D.; Qian, Y.; Ohkanda, J.; Bailey, R. D.; Hamilton, A. D.; Sebti, S. M. Antitumor Efficacy of a Novel Class of Non-Thiol-Containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine. Cancer Res. 1999, 59, 4919-4926.
72. Hoover, R. R.; Mahon, F.-X.; Melo, J. V.; Daley, G. Q. Overcoming STI571 Resistance with the Farnesyl Transferase Inhibitor SCH66336. Blood 2002, 100, 1068-1071.
73. Nakajima, A.; Tauchi, T.; Sumi, M.; Bishop, W. R.; Ohyashiki, K. Efficacy of SCH66336, a Farnesyl Transferase Inhibitor, in Conjunction with Imatinib against BCR-ABL-positive Cells. Mol. Cancer Ther. 2003, 2, 219-224.
74. Hahn, S. M.; Bernhard, E. J.; Regine, W.; Mohiuddin, M.; Haller, D. G.; Stevenson, J. P.; Smith, D.; Pramanik, B.; Tepper, J.; DeLaney, T. F.; Kiel, K. D.; Morrison, B.; Deutsch, P.; Muschel, R. J.; McKenna, W. G. A Phase 1 Trial of the Farnesyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Lung and Head and Neck Cancer. Clin. Cancer Res. 2002, 8, 1065-1072.
75. Adjei, A. A.; Croghan, G. A.; Erlichman, C.; Marks, R. S.; Reid, J. M.; Sloan, J. A.; Pitot, H. C.; Alberts, S. R.; Goldberg, R. M.; Hanson, L. J.; Bruzek, L. M.; Atherton, P.; Thibault, A.; Palmer, P. A.; Kaufmann, S. H. A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer. Clin. Cancer Res. 2003, 9, 2520-2526.
76. Van Cutsem, E.; Karasek, P.; Oettle, H.; Vervenne, W. L.; Szawlowski, A. ; Schoffski, P.; Past, S.; Neumann, H.; Safran, H.; Humblet, Y.; van de Velde, H.; Ma, Y.; Von Hoff, D. Phase III Trial Comparing Gemcitabine + R115777 (Zarnestra) versus Gemcitabine + Placebo in Advanced Pancreatic Cancer (PC). Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, 2002; Abstract 517.